Comparing appendix removal to biologic therapy for left-sided ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This trial compares two treatments for left-sided ulcerative colitis that hasn't responded to standard care: surgery to remove the appendix versus a biologic drug called an anti-TNF. The goal is to see which one better achieves remission in both symptoms and colon healing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of ulcerative colitis affecting the left side of the colon (up to the middle part of the colon).
- Your disease is still active despite standard treatments, and you are considered a candidate for anti-TNF therapy (a type of biologic).
- You must be willing to have surgery to remove your appendix (appendectomy).
- You cannot have had your appendix removed before, nor had major abdominal surgery that could make appendectomy riskier.
- You must not have severe acute colitis or toxic megacolon, and cannot be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This trial compares two ways of reconnecting the bowel after subtotal colectomy and ileostomy in people with ulcerative colitis (UC). It may help determine which surgical option works best when the rectum is calm enough to manage with topical mesalazine alone.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
This trial tests whether fecal microbiota transfer (a stool-based therapy) can improve outcomes when added to starting a new biologic medicine for ulcerative colitis. It compares fecal transplant versus placebo (a sham treatment) to see if symptoms and inflammation improve faster or more strongly.
This trial compares how well different combinations of drugs calm inflammation in the gut compared to single drugs. It uses tissue samples taken during a colonoscopy to see which approach works best for people with inflammatory bowel disease.
This trial compares different biologic medications to see which best prevents Crohn's disease from coming back after intestinal surgery. It may help you if you have had surgery for Crohn's and are starting a biologic drug soon after.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.